Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928327 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03928327 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT03928327, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the effect of itraconazole (Part 1) and rifampin (Part 2) on the single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult participants.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG TAK-788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2019-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03928327
The ClinicalTrials.gov registry entry for NCT03928327 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT03928327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03928327 about?
NCT03928327 is a clinical study titled "A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants". The purpose of this study is to characterize the effect of itraconazole (Part 1) and rifampin (Part 2) on the single-dose pharmacokinetics (PK) of TAK-788 and its active metabolites (AP32960 and AP32914) in healthy adult participants.
What is the current status of trial NCT03928327?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-05-02. Estimated completion is 2019-08-16.
What interventions are being tested in trial NCT03928327?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), TAK-788 (DRUG).
Who is sponsoring clinical trial NCT03928327?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.